Return-to-Play for Athletes With Long QT Syndrome or Genetic Heart Diseases Predisposing to Sudden Death

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

卷:78

Article

Tobert, Kathryn E.¹  Bos, J. Martijn^1,2,3  Garmany, Ramin^1,4,5  Ackerman, Michael J.^1,2,3 

[1] Mayo Clin, Windland Smith Rice Sudden Death Genom Lab, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA

[2] Mayo Clin, Div Heart Rhythm Serv, Dept Cardiovasc Med, Windland Smith Rice Genet Heart Rhythm Clin, Rochester, MN 55905 USA

[3] Mayo Clin, Dept Pediat & Adolescent Med, Div Pediat Cardiol, Rochester, MN 55905 USA

[4] Mayo Clin, Grad Sch Biomed Sci, Alix Sch Med, Rochester, MN 55905 USA

[5] Mayo Clin Med Scientist Training Program, Rochester, MN USA

关键词: athlete;    genetic heart disease;    long QT syndrome;    return to play;    RTP;    shared decision making;    sudden cardiac death;   

DOI  :  10.1016/j.jacc.2021.04.026

来源: Elsevier

【 摘 要 】

BACKGROUND Within the last 5 years, cardiac society guidelines have begun to acknowledge shared decision making (SDM) for the athlete with sudden cardiac death-predisposing genetic heart diseases (GHDs), such as long QT syndrome (LQTS), and the possibility for that athlete's return to play. Previously, international guidelines embraced a de facto disqualification for all such athletes including athletes with solely a positive genetic test in Europe. OBJECTIVES This study sought to examine the prevalence and outcomes of athletes with sudden cardiac death-predisposing GHDs, particularly LQTS, after their return to play. METHODS A retrospective review of the electronic medical record was performed on all athletes with GHD, with a primary analysis for those with LQTS, who were evaluated, risk stratified, and treated in Mayo Clinic's Windland Smith Rice Genetic Heart Rhythm Clinic by a single genetic cardiologist between July 1, 2000, and July 31, 2020. RESULTS There were 672 athletes with GHD overall including 494 athletes with LQTS (231 female athletes [46.8%]; mean age at diagnosis 14.8 +/- 10.5 years; mean follow-up 4.2 +/- 4.8 years) who were given return-to-play approval. Overall, 79 of 494 athletes with LQTS (16.0%) were symptomatic before diagnosis, and 58 (11.7%) had an implantable cardioverter-defibrillator. In 2,056 combined years of follow-up, there was no GHD-sports associated mortality. Instead, 29 patients (5.9%) had >= 1 nonlethal, LQTS-associated breakthrough cardiac event. Of those, 15 (3.0%) were athletes at the time of the breakthrough cardiac event, with 3 (0.6%) experiencing a sports-related breakthrough cardiac event, and 12 (2.4%) a non-sports-related event. Overall, the event rate was 1.16 nonlethal events per 100 athlete-years of follow-up. CONCLUSIONS This 20-year single center experience challenges the status quo of disqualification for all athletes with LQTS and provides additional observational evidence, albeit from a single center, in support of the more contemporary SDM approaches to this complex issue. (C) 2021 by the American College of Cardiology Foundation.

【 授权许可】

Free